U.S., April 18 -- ClinicalTrials.gov registry received information related to the study (NCT06932705) titled 'A Study to Compare to PK Characteristics and Safety Profiles Between PA-111 and PA-111A' on April 10.
Brief Summary: Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of PA-111 in healthy subjects.
Study Start Date: April, 2025
Study Type: INTERVENTIONAL
Condition:
Mixed Dyslipidemia
Intervention:
DRUG: PA-111
PA-111 1Tab., Per Oral
DRUG: PA-111A
PA-111A 1Capsule., Per Oral
Recruitment Status: RECRUITING
Sponsor: Addpharma Inc.
Published by HT Digital Content Services with permission from Health Daily Digest....